Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Amortization of Deferred Charges (2017 - 2023)

Standard Biotools (LAB) has disclosed Amortization of Deferred Charges for 7 consecutive years, with $173000.0 as the latest value for Q4 2023.

  • Quarterly Amortization of Deferred Charges fell 14.36% to $173000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $770000.0 through Dec 2023, down 7.23% year-over-year, with the annual reading at $770000.0 for FY2023, 7.23% down from the prior year.
  • Amortization of Deferred Charges for Q4 2023 was $173000.0 at Standard Biotools, down from $187000.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $2.0 million in Q1 2019, with the low at -$194000.0 in Q4 2019.
  • Average Amortization of Deferred Charges over 5 years is $269500.0, with a median of $194500.0 recorded in 2022.
  • The sharpest move saw Amortization of Deferred Charges plummeted 107.28% in 2019, then surged 205.0% in 2021.
  • Over 5 years, Amortization of Deferred Charges stood at -$194000.0 in 2019, then soared by 167.01% to $130000.0 in 2020, then surged by 228.46% to $427000.0 in 2021, then tumbled by 52.69% to $202000.0 in 2022, then dropped by 14.36% to $173000.0 in 2023.
  • According to Business Quant data, Amortization of Deferred Charges over the past three periods came in at $173000.0, $187000.0, and $206000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.